Good morning :)
$
₹
Aquestive Therapeutics Inc

Aquestive Therapeutics Inc

AQST

NASDAQ
Asset Logo

Aquestive Therapeutics Inc

AQST

NASDAQ
$3.601.53% (-0.05)
$
₹
$3.601.53% (-0.05)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Small Cap

With a market cap of $476.9M the stock is ranked 3339

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

14.14
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.66
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-144.63%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 9 analysts reports

Buy
9 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+155.01%

Earnings Growth

+39.19%

Rev. Growth

+14.58%

See Detailed Forecast

Company Profile

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.74
45.74
1Y Return
44.64%
44.64%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.93
41.93
1Y Return
48.67%
48.67%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
151.87
151.87
1Y Return
71.05%
71.05%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
31.48
31.48
1Y Return
28.42%
28.42%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.73
26.73
1Y Return
10.56%
10.56%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 155.01% growth, versus a trailing 3-year CAGR of 30.95%.

2026
Current$3.66Baseline
Analyst Target - 1 year
Target$9.33+155.01%

All values in $

202220232024202520262027$3.17$5.54$7.90Target+155.01%
2026
Current$3.66Baseline
Analyst Target - 1 year
Target$9.33+155.01%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 14.58% growth, versus a trailing 3-year CAGR of -2.24%.

2025
Current$44.54Baseline
Forecast for Dec 2026
High$59.26+33.05%
Average$51.03+14.58%
Low$49.17+10.39%

All values in $ Million

20212022202320242025202650.8347.6850.5857.5644.54Low+10.39%Average+14.58%High+33.05%
2025
Current$44.54Baseline
Forecast for Dec 2026
High$59.26+33.05%
Average$51.03+14.58%
Low$49.17+10.39%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.74Baseline
Forecast for Dec 2026
High$-0.45+39.19%
Average$-0.45+39.19%
Low$-0.45+39.19%

All values in $

202120222023202420252026-1.84-1.14-0.34-0.45-0.74Low+39.19%Average+39.19%High+39.19%
2025
Current$-0.74Baseline
Forecast for Dec 2026
High$-0.45+39.19%
Average$-0.45+39.19%
Low$-0.45+39.19%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

13
-31.8
14.4
-8
13.8
-22.8
7.5
-16.4
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue20.0913.5411.868.721012.8013.0114.4413.817.55
Net Income-2.74-11.50-17.05-22.93-13.54-15.44-31.86-8.05-22.86-16.49
Net Profit Margin-13.65%-84.98%-143.71%-262.95%-135.43%-120.60%-244.79%-55.77%-165.45%-218.28%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Aquestive Therapeutics Inc -14.14-
Eli Lilly and Company45.7431.171.32
Johnson & Johnson41.937.852.99
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare AQST with any stock or ETF
Compare AQST with any stock or ETF
Comparing from
AQST
LLY
JNJ
Loading...

Frequently asked questions

  1. Aquestive Therapeutics Inc (AQST) share price today is $3.60 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $3.74 and a day low of $3.55.

  2. Aquestive Therapeutics Inc stock trades on NASDAQ under the ticker symbol AQST.

  3. Aquestive Therapeutics Inc's market capitalization is $476.94M as of November 7, 2026 at 2:29 AM IST.

  4. Aquestive Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of November 7, 2026.

  5. Aquestive Therapeutics Inc's price-to-book (P/B) ratio is 14.14 as of November 7, 2026.

  6. Yes, You can buy Aquestive Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Aquestive Therapeutics Inc shares in three steps: 1. Search Aquestive Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Aquestive Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Aquestive Therapeutics Inc (AQST) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.7746 shares at the current price of $3.60.

Loading...